Immobilized human PD-L1 at 0.5 μg/ml (50 μL/well) can bind to Atezolizumab with a linear range of 1.221 ng/ml-5 μg/ml.
Anti-PD-L1 Monoclonal Antibody(Atezolizumab)
Anti-PD-L1 Monoclonal Antibody(Atezolizumab)
Price:
Regular price
$383.00 SGD
Regular price
Sale price
$383.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | PD-L1 |
| Synonyms | Programmed cell death 1 ligand 1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1 |
| Accession | Q9NZQ7 |
| Clone Number | S-SC015 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of PD-1/PD-L1 signaling Functional assays |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ELISA | 1.221-5000 ng/ml |
Background
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Picture
Picture
ELISA
